Merck Announces Pivotal Phase 3 TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints Of OS And PFS In Certain Patients With Endometrial Cancer

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Comments

No comments yet. Be the first!